A novel anticholinesterase THB013: Biochemical and behavioural studies

A. Adem, A. H. Mohammed, B. Winblad, B. E. Henriksson

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)


Clinical trials with tacrine (THA) have resulted in elevations of liver enzymes in Alzheimer patients that showed improvement. In an effort to minimize these side effects several THA analogues were synthesized. These analogues were compared to THA in biochemical as well as behavioural studies. In this study, the biochemical effects of THA and one of these analogs, THB 013, on plasma cholinesterase activity, cholinergic receptors as well as the effect of these drugs on spatial learning in adult rats were examined. THB 013 was, at lower concentration, more efficacious in inhibiting plasma cholinesterase as well as blocking the scopolamine induced disruption of spatial learning when administered 10 min before the scopolamine injection. It is possible that THB 013 with more potent cholinergic effects than THA might be useful in the treatment of Alzheimer's disease.

Original languageEnglish
Pages (from-to)139-148
Number of pages10
JournalJournal of Neural Transmission - Parkinsons Disease and Dementia Section
Issue number1-2
Publication statusPublished - Feb 1 1994
Externally publishedYes


  • Alzheimer's disease
  • THB 013
  • acetylcholine release
  • cholinergic
  • cholinesterases
  • muscarinic
  • spatial learning
  • tacrine
  • tacrine analogues

ASJC Scopus subject areas

  • General Neuroscience
  • Clinical Neurology


Dive into the research topics of 'A novel anticholinesterase THB013: Biochemical and behavioural studies'. Together they form a unique fingerprint.

Cite this